描述
Sofosbuvir is a nucleotide analog prodrug that inhibits the HCV NS5B RNA-dependent RNA polymerase, essential for viral replication Nature+15PMC+15European Medicines Agency (EMA)+15. It is the active component in the brand Sovaldi, characterized by a yellow, film-coated tablet containing 400?mg of sofosbuvir.
This formulation is ideal for preclinical research focusing on viral replication, drug resistance mechanisms, combination therapy models, and biochemical pharmacology involving HCV. Although clinically approved for hepatitis C treatment, this product is supplied for laboratory research and wholesale use.
Sofosbuvir Tablets Product Specifications
Parameter | Details |
---|---|
Product Name | Sofosbuvir Tablets (Sovaldi) |
Generic Name | Sofosbuvir |
CAS Number | 1190307?88?0 |
Molecular Formula | C??H??FN?O?P |
Molecular Weight | ~529.45?g/mol |
Strength | 400?mg per tablet |
Quantity | 28 tablets per bottle |
Dosage Form | Film?coated oral tablet |
Approval Number | HJ20170365 (China) |
Manufacturer | Gilead Sciences Ireland UC |
Barcode | [Contact for barcode] |
Storage Conditions | Store ??30?°C; keep in original container |
Intended Use | Laboratory research: HCV virology, antiviral screening, enzymology |
Sofosbuvir Tablets Mechanism of Action
Sofosbuvir is metabolized in hepatocytes to its active triphosphate form, which competitively blocks the HCV NS5B polymerase, causing premature termination of RNA synthesis . This inhibition applies across all major HCV genotypes and has a high barrier to resistance.
Sofosbuvir Tablets Research Applications
-
Viral replication assays targeting NS5B polymerase
-
Resistance profiling for direct-acting antivirals (DAAs)
-
Combination antiviral screening (e.g., sofosbuvir + velpatasvir)
-
Studies of activation/metabolism pathways in hepatocytes
-
Mechanistic research into HCV virology and pharmacodynamics
Safety & Handling
-
Use standard laboratory PPE (lab coat, gloves, eye protection)
-
Conduct all handling in research-grade conditions
-
Store in a sealed container away from heat and moisture
-
Not for human or veterinary clinical use
Core Keywords
sofosbuvir tablets 400mg, Sovaldi, CAS 1190307-88-0, HCV NS5B inhibitor, HCV research compound, nucleotide analog sofosbuvir, antiviral screening drug, Gilead sofosbuvir tablet, hepatitis C lab reagent
Research Use Disclaimer
This product is intended only for laboratory and preclinical research. It is not approved for clinical, diagnostic, therapeutic, or veterinary application. Misuse may result in health or regulatory consequences. Use responsibly following institutional protocols.
评价
目前还没有评价